Your browser doesn't support javascript.
loading
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Voss, Martin H; Bhatt, Rupal S; Vogelzang, Nicholas J; Fishman, Mayer; Alter, Robert S; Rini, Brian I; Beck, J Thaddeus; Joshi, Monika; Hauke, Ralph; Atkins, Michael B; Burgess, Earle; Logan, Theodore F; Shaffer, David; Parikh, Rahul; Moazzam, Nauman; Zhang, Xiaosha; Glasser, Chad; Sherman, Matthew L; Plimack, Elizabeth R.
Affiliation
  • Voss MH; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bhatt RS; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Vogelzang NJ; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada.
  • Fishman M; Moffit Cancer Center, Tampa, Florida.
  • Alter RS; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
  • Rini BI; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
  • Beck JT; Highlands Oncology Group, Fayetteville, Arkansas.
  • Joshi M; Penn State Cancer Institute, Hershey, Pennsylvania.
  • Hauke R; Nebraska Methodist Hospital, Omaha, Nebraska.
  • Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
  • Burgess E; Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina.
  • Logan TF; Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
  • Shaffer D; New York Oncology Hematology, Albany, New York.
  • Parikh R; University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
  • Moazzam N; Rocky Mountain Cancer Centers, Aurora, Colorado.
  • Zhang X; Acceleron Pharma Inc, Cambridge, Massachusetts.
  • Glasser C; Acceleron Pharma Inc, Cambridge, Massachusetts.
  • Sherman ML; Acceleron Pharma Inc, Cambridge, Massachusetts.
  • Plimack ER; Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Cancer ; 125(14): 2400-2408, 2019 07 15.
Article in En | MEDLINE | ID: mdl-30951193
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Immunoglobulin Fc Fragments / Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Angiogenesis Inhibitors / Activin Receptors, Type II / Axitinib / Kidney Neoplasms Type of study: Clinical_trials / Etiology_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Immunoglobulin Fc Fragments / Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Angiogenesis Inhibitors / Activin Receptors, Type II / Axitinib / Kidney Neoplasms Type of study: Clinical_trials / Etiology_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2019 Type: Article